CARsgen Therapeutics Holdings Limited (CARsgen-B) reported interim results for the six months ended 30 June 2026, showing continued commercial progress of its CAR-T portfolio and a strengthened cash position.

Revenue and Profitability • Revenue increased 21.4% year on year to RMB 62.00 million, driven by higher sales of the autologous BCMA CAR-T therapy zevorcabtagene autoleucel (zevor-cel). • Gross profit rose 44.8% to RMB 42.02 million, supported by cost efficiencies from in-house plasmid and vector production. • Net loss narrowed 5.0% to RMB 70.84 million. Adjusted net loss (excluding share-based compensation) fell 55.6% to RMB 31.93 million.

Cash and Capital Resources • Cash and cash equivalents reached RMB 1.40 billion at 30 June 2026, up from RMB 1.12 billion at end-2025, aided by a RMB 405 million top-up placing completed in May 2026. • Management expects year-end cash to remain above RMB 1.20 billion, providing liquidity through 2030.

Commercial and Pipeline Milestones • Zév or-cel: 110 confirmed orders from Huadong Medicine during 1H 2026; commercialization progressing across more than 20 Chinese provinces. • Satricabtagene autoleucel (satri-cel): Received NMPA approval in June 2026 for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction cancer, marking the world’s first approved CAR-T for solid tumors. Domestic launch underway with prioritized rollout to leading oncology centers. • Allogeneic platform THANK-u Plus®: IND clearances obtained for CT0596 (BCMA, R/R MM) and CT1190B (CD19/CD20, R/R LBCL); Phase I registrational trials to start. • In vivo CARvivo® platform: Investigator-initiated trial of KJ-C2529 (CD19/CD20) for B-cell malignancies initiated. • Manufacturing expansion: New Jinshan manufacturing base in Shanghai announced, with planned investment up to RMB 370 million to support global-standard production.

Operating Metrics • R&D expenses were largely stable at RMB 132.46 million (+1.7% YoY). • Administrative expenses decreased 13.5% to RMB 34.47 million. • Selling and distribution costs rose to RMB 12.26 million as the company built a dedicated commercial team for satri-cel.

Outlook Management intends to accelerate commercialization of zevor-cel and satri-cel, advance allogeneic and in vivo CAR-T programs, and expand manufacturing capacity while maintaining sufficient cash to fund operations into 2030.